Merck's Sac-TMT Beats Chemo in Lung Cancer — Keytruda's Cliff Answer

Merck just did something the cholesterol world has chased for fifteen years — it put a PCSK9 inhibitor in a pill, and it beat AstraZeneca to the FDA to do it.

And that's not even Merck's only win this week. Lilly bought a psychedelics company, Celcuity got approved and lost a fifth of its value the same day, and Europe cleared the Wegovy pill. Busy Thursday. Let's get into it.

Welcome to The Pharma Closeout for Thursday, July 16th, 2026. I'm Alex Mercer.

And I'm Maya Patel.

Here's what's actually happening. Merck's Lipfendra — enlicitide — got FDA approval this morning as the first oral PCSK9 inhibitor. Every drug in this class until today has been an injectable. Repatha. Praluent. Merck just turned the mechanism into a once-daily tablet.

And the how is the whole story. It's a macrocyclic peptide — getting a peptide to survive the gut and still bind PCSK9 is the problem that kept this class in a syringe for a decade. Merck didn't out-market the injectables. They solved a formulation problem nobody else cracked.

And the data earns the launch. CORALreef Lipids — a placebo-adjusted fifty-six percent LDL cut at week twenty-four. CORALreef HeFH, the familial population — fifty-nine percent. That's injectable-grade lowering in a pill you swallow with your coffee.

OK, but here's my issue with calling this a market reset today. Those are LDL-C numbers. Excellent ones. But there's no cardiovascular outcomes data yet — does fifty-six percent actually translate into fewer heart attacks? The injectables earned their positioning on outcomes trials. Merck is launching on the surrogate.

That's fair — but the surrogate is enough to open the door here. LDL lowering is the most validated marker in cardiovascular medicine, and payers already reimburse against it. The outcomes trial deepens the label later. It doesn't gate the launch now.

Then the sharper read is who writes the script. Injectable PCSK9s live with cardiologists and lipid clinics. A once-daily pill walks straight into primary care — a prescriber base ten times the size. That's the real expansion. Not the efficacy number, the pharmacy counter.

And one number to keep honest — the fifty-six is the placebo-adjusted primary. Merck also disclosed a sixty percent drop from baseline after stripping out biologically impossible baseline values under revised data rules. That's a post-hoc cut.

Which is exactly the footnote that matters. Model this against Repatha on the fifty-six, not the sixty. And watch tolerability — diarrhea and dizziness ran higher than placebo in the HeFH arm, single digits, but this is a pill people take for thirty years. In chronic prevention, tolerability is the whole commercial game.

The competitive read: if you run strategy anywhere in cardiometabolic, AstraZeneca's oral PCSK9 is still in Phase 1. Merck just claimed the entire first-mover window in oral lipid lowering — and Amgen and Regeneron-Sanofi now have an oral rival on their most defensible mechanism.

And the open thread is durability of that lead — whether Merck converts a clean approval into primary-care habit before the outcomes data, or a competitor, forces the conversation. The label got them in the room. Adoption is the business.

Now the deal that had my inbox lighting up. Eli Lilly is buying AtaiBeckley — six dollars seventy-five a share, cash, roughly two point eight billion upfront. Twenty-six percent over Wednesday's close, forty percent over the thirty-day average. Lilly's eleventh acquisition this year. And the structure has a tail — let's bring in Marcus Webb on this one.

And it validates a field Big Pharma waved off for years — psychedelics for treatment-resistant depression, head-to-head against J&J and Spravato.

Here's the piece to hold onto. BPL-003 is intranasal mebufotenin, and the Phase 2b showed separation from placebo starting Day 2, held through Day 57. Lilly's Skovronsky says patients might dose a couple times a year. If that durability survives Phase 3, this isn't a daily antidepressant — it's an episodic, administered therapy. That rewrites reimbursement and the delivery infrastructure from scratch.

Rapid fire on the rest, because it was a heavy tape. Ligand closed its XOMA Royalty buy at thirty-nine a share — north of two hundred royalty assets now. Novartis paid one point one billion upfront for Myricx Bio and a next-gen ADC payload. AstraZeneca took rights to Dizal's lung cancer pill, six hundred million upfront — the deal we flagged Monday, targeted to close in the second half.

And staying with Merck for a second — they also touted a front-line Keytruda win in an endometrial cancer subtype yesterday. Easy to miss under the PCSK9 headline, but it's the kind of quiet label expansion that keeps a franchise growing while everyone's watching the shiny new pill.

Good catch. And on the litigation front, Sanofi sued Pfizer and Moderna over mRNA patents — the IP wars just added a third combatant.

The through-line: first-half M&A already ran to a hundred and thirty-four billion across thirty-three billion-dollar-plus deals, and Lilly is the most aggressive buyer in the industry. If you're a mid-cap with a validated platform, you're on a list somewhere.

On the regulatory front, the strangest chart of the day belongs to Celcuity. The FDA approved its breast cancer drug, Revtorpyk — and the stock fell nearly twenty percent. Not on efficacy. On a disclosed launch delay, plus prescribing-information details that blindsided analysts.

An approval-day sell-off. That's the market pricing execution, not science.

Right — and it circles back to Monday. We asked whether Celcuity stays a standalone or becomes a target once the AstraZeneca-Dizal deal frames the landscape. A launch stumble like this is precisely what pulls a target's valuation into range. The label got approved. The execution question just got louder.

Also worth noting on the regulatory front — Europe cleared the Wegovy pill this week. That hands Novo an oral obesity head start on Lilly's orforglipron in that market.

And that flips the script we've run for months. We've framed Lilly-versus-Novo as tilting toward Lilly. On oral obesity in Europe, Novo got there first — the read isn't that Lilly's behind on the molecule, it's that Novo bought a timing window it now has to monetize before orforglipron lands.

One more, and it's genuinely odd — Kalshi is now letting people bet on clinical trial outcomes and FDA decisions.

Which sounds like a novelty until you ask who's trading. Binary catalysts are what this industry runs on. Financialize them and you've opened a real conversation about information asymmetry and disclosure. If you sit in investor relations, that's not a curiosity — that's a compliance question forming.

Looking ahead. Abbott reported this morning — a Q2 beat, raised full-year profit guidance. Sets a constructive tone for the device and diagnostics names reporting behind it.

And on the flip side, small caps are getting punished on financings. VivoSim down more than twenty-five percent on a four-million-dollar raise. Q32 Bio pricing at eighteen and a quarter. Oruka hit after a three-and-a-half-million-share block came loose. Strong tape, brutal terms.

Watch three things. Whether Merck's oral PCSK9 pulls primary-care scripts fast. The AstraZeneca-Dizal close in the second half. And Lilly's next target — because eleven deals in, they are not done.

And keep one eye on Biogen — new tau data this week backed diranersen into Phase 3 despite a missed primary endpoint. That's a bet on the mechanism over the headline, and it's the kind of thread that either vindicates the anti-tau approach or doesn't. Worth tracking.

And that is your Pharma Closeout for Thursday, July 16th — Merck's oral PCSK9 pill, Lilly's two-point-eight-billion psychedelics bet, Celcuity's approval-day drop, and the Wegovy pill clearing Europe. One day, three franchises rewritten. If you want to stay across this space, subscribe wherever you listen and drop a rating — we're back tomorrow.

It moved on every front today. Go enjoy your evening — we'll be back tomorrow with the first read on whatever Lilly does next. See you then!